Progression of Ebola therapeutics during the 2014-2015 outbreak

Trends in Molecular Medicine

Volumn 22, Issue 2, 2016, Pages 164-173

  Mendoza, Emelissa J ^a,b   Qiu, Xiangguo ^a,b   Kobinger, Gary P ^a,b,c  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Ebola virus therapeutics; Infectious disease outbreak

Indexed keywords

AMIODARONE; BRINCIDOFOVIR; FAVIPIRAVIR; MONOCLONAL ANTIBODY; SMALL INTERFERING RNA; TKM EBOLA; ZMAPP; ANTIVIRUS AGENT; MOLECULAR LIBRARY; NEUTRALIZING ANTIBODY;

ANTIBODY PRODUCTION; CLINICAL EVALUATION; CLINICAL OBSERVATION; CLINICAL TRIAL (TOPIC); COMPASSIONATE USE; CONVALESCENCE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG REPOSITIONING; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; EPIDEMIC; HUMAN; NONHUMAN; REVIEW; TREATMENT INDICATION; ANIMAL; DISEASE OUTBREAKS; DRUG EFFECTS; GUINEA; HEMORRHAGIC FEVER, EBOLA; IMMUNOLOGY; LIBERIA; MOLECULAR LIBRARY; PATHOGENICITY; PHYSIOLOGY; SIERRA LEONE; THERAPEUTIC USE; VIROLOGY; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; COMPASSIONATE USE TRIALS; DISEASE OUTBREAKS; EBOLAVIRUS; GUINEA; HEMORRHAGIC FEVER, EBOLA; HUMANS; LIBERIA; RNA, SMALL INTERFERING; SIERRA LEONE; SMALL MOLECULE LIBRARIES; VIRUS REPLICATION;

EID: 84960470974     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2015.12.005     Document Type: Review

References (58)

1. WHO Ebola Situation Report - 9 December 2015 2015, WHO.
2. Meyers L., et al. Ebola virus outbreak 2014: clinical review for emergency physicians. Ann. Emerg. Med. 2015, 65:101-108.
3. Nkoghe D., et al. Cutaneous manifestations of filovirus infections. Int. J. Dermatol. 2012, 51:1037-1043.
4. Rowe A.K., et al. Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epidémies à Kikwit. J. Infect. Dis. 1999, 179(Suppl.):S28-S35.
5. Feldmann H., et al. Filoviridae: Marburg and Ebola viruses. Fields Virology 2013, 1410-1448. Lippincott Williams & Wilkins. D.M. Knipe (Ed.).
6. WHO Ethical Considerations for Use of Unregistered Interventions for Ebola Virus Disease 2014, WHO.
7. Kass N. Ebola, ethics, and public health: what next?. Ann. Intern. Med. 2014, 161:744.
8. Caplan A.L., et al. Selecting the right tool for the job. Am. J. Bioeth. 2015, 15:4-10.
9. Li T.C.M., et al. Clinical implications of antiviral resistance in influenza. Viruses 2015, 7:4929-4944.
10. Janeba Z. Development of small-molecule antivirals for Ebola. Med. Res. Rev. 2015, 35:1175-1194.
11. Salata C., et al. Amiodarone and metabolite MDEA inhibit Ebola virus infection by interfering with the viral entry process. Pathog. Dis. 2015, 73:ftv032.
12. Gehring G., et al. The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry. J. Antimicrob. Chemother. 2014, 69:2123-2131.
13. Smither S.J., et al. Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model. Antivir. Res. 2014, 104:153-155.
14. Florescu D.F., et al. Administration of brincidofovir and convalescent plasma in a patient with Ebola virus disease. Clin. Infect. Dis. 2015, 61:969-973.
15. Wolf T., et al. Severe Ebola virus disease with vascular leakage and multiorgan failure: treatment of a patient in intensive care. Lancet 2015, 385:1428-1435.
16. Gupta-Wright A., et al. Concerns about the off-licence use of amiodarone for Ebola. BMJ 2015, 350:h272.
17. Schibler M., et al. Clinical features and viral kinetics in a rapidly cured patient with Ebola virus disease: a case report. Lancet Infect. Dis. 2015, 15:1034-1040.
18. Mora-Rillo M., et al. Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease contracted in Madrid, Spain. Lancet Respir. Med. 2015, 3:554-562.
19. ClinicalTrials.gov Clinical Study to Assess Efficacy and Safety of Amiodarone in Treating Patients With Ebola. Virus Disease (EVD) in Sierra Leone. EASE (EMERGENCY Amiodarone Study Against Ebola) 2014, Clinicaltrials.gov.
20. ClinicalTrials.gov An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease 2014, Clinicaltrials.gov.
21. Kupferschmidt K., Cohen J. Infectious diseases. Ebola drug trials lurch ahead. Science 2015, 347:701-702.
22. ClinicalTrials.gov Efficacy of Favipiravir Against Ebola (JIKI) 2014, Clinicaltrials.gov.
23. Bouazza N., et al. Favipiravir for children with Ebola. Lancet 2015, 385:603-604.
24. MSF Preliminary Results of the JIKI Clinical Trial to Test the Efficacy of Favipiravir in Reducing Mortality in Individuals Infected by Ebola Virus in Guinea 2014, MSF.
25. FDA Guidance for Industry-Product Development under the Animal Rule 2014, FDA.
26. Marty F.M., et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N. Engl. J. Med. 2013, 369:1227-1236.
27. Singh S.N., et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N. Engl. J. Med. 1995, 333:77-82.
28. Furuta Y., et al. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antivir. Res. 2013, 100:446-454.
29. Geisbert T.W., et al. Considerations in the use of nonhuman primate models of Ebola virus and Marburg virus infection. J. Infect. Dis. 2015, 212(Suppl. 2):S91-S97.
30. ClinicalTrials.gov Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults 2015, Clinicaltrials.gov.
31. Van Griensven J., et al. The use of Ebola convalescent plasma to treat Ebola virus disease in resource-constrained settings: a perspective from the field. Clin. Infect. Dis. 2015, 62:69-74.
32. Mupapa K., et al. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J. Infect. Dis. 1999, 179(Suppl.):S18-S23.
33. Erhabor O., Adias T.C. From whole blood to component therapy: the economic, supply/demand need for implementation of component therapy in sub-Saharan Africa. Transfus. Clin. Biol. 2011, 18:516-526.
34. Jahrling P.B., et al. Ebola hemorrhagic fever: evaluation of passive immunotherapy in nonhuman primates. J. Infect. Dis. 2007, 196(Suppl.):S400-S403.
35. Dye J.M., et al. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:5034-5039.
36. ClinicalTrials.gov Clinical Trial to Evaluate the Efficacy and Safety of Convalescent Plasma for Ebola Treatment (EVD001) 2015, Clinicaltrials.gov.
37. ClinicalTrials.gov Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Guinea (Ebola-Tx) 2015, Clinicaltrials.gov.
38. ISRCTN Convalescent Plasma for Early Ebola Virus Disease in Sierra Leone 2015, ISRCTN.
39. Wong G., Kobinger G.P. Backs against the wall: novel and existing strategies used during the 2014-2015 Ebola virus outbreak. Clin. Microbiol. Rev. 2015, 28:593-601.
40. Haasnoot J., et al. The Ebola virus VP35 protein is a suppressor of RNA silencing. PLoS Pathog. 2007, 3:e86.
41. Hoenen T., et al. Infection of naive target cells with virus-like particles: implications for the function of ebola virus VP24. J. Virol. 2006, 80:7260-7264.
42. Volchkov V.E., et al. Characterization of the L gene and 5' trailer region of Ebola virus. J. Gen. Virol. 1999, 80:355-362.
43. Geisbert T.W., et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 2010, 375:1896-1905.
44. Thi E.P., et al. Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates. Nature 2015, 521:362-365.
45. Gao J., Yin L. Drug development for controlling Ebola epidemic - a race against time. Drug Discov. Ther. 2014, 8:229-231.
46. ClinicalTrials.gov Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study for Intravenous (IV) TKM-100802 2014, Clinicaltrials.gov.
47. Kraft C.S., et al. The use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States. Clin. Infect. Dis. 2015, 61:496-502.
48. PACTR Rapid Assessment of Potential Interventions & Drugs for Ebola (RAPIDE) 2015, PACTR.
49. Qiu X., et al. Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies. Clin. Immunol. 2011, 141:218-227.
50. Qiu X., et al. Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci. Transl. Med. 2012, 4:138ra81.
51. Pettitt J., et al. Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci. Transl. Med. 2013, 5:199ra113.
52. Qiu X., et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 2014, 514:47-53.
53. Davidson E., et al. Mechanism of binding to Ebola virus glycoprotein by the ZMapp, ZMAb, and MB-003 cocktail antibodies. J. Virol. 2015, 89:10982-10992.
54. ClinicalTrials.gov Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection 2015, Clinicaltrials.gov.
55. ClinicalTrials.gov Safety and Pharmacokinetics of a Single ZMappTM Administration in Healthy Adult Volunteers 2015, Clinicaltrials.gov.
56. Lyon G.M., et al. Clinical care of two patients with Ebola virus disease in the United States. N. Engl. J. Med. 2014, 371:2402-2409.
57. Hellwig S., et al. Plant cell cultures for the production of recombinant proteins. Nat. Biotechnol. 2004, 22:1415-1422.
58. Kelley B. Industrialization of mAb production technology: the bioprocessing industry at a crossroads. MAbs 2009, 1:443-452.